Filter By:

Binimetinib

04/19/2015

American Association for Cancer Research Annual Meeting

Evaluation of the nonclinical activity of the MEK inhibitor binimetinib (MEK162) in combination with paclitaxel in PDX models of HGSOC

S. Winski, et al.

Encorafenib

04/18/2015

American Association for Cancer Research Annual Meeting

Phase 1 Study of the Selective BRAFV600 Inhibitor Encorafenib (LGX818) Combined With Cetuximab and With or Without the α-specific PI3K Inhibitor Alpelisib (BYL719) in Patients With Advanced BRAF-mutant Colorectal Cancer

J. Schellens, M.D., et al.

ARRY-614

12/08/2014

American Society of Hematology Annual Meeting

Efficacy of Dual Inhibition of p38 Mitogen Activated Protein Kinase (MAPK) and Tie-2 Kinase in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

L.S. Bachegowda MD MRCP, et al.

ARRY-614

12/05/2014

Clinical Cancer Research

A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

G. Garcia-Manero, et al.

Encorafenib

11/18/2014

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Phase 1b Study of the Selective BRAFV600 Inhibitor Encorafenib (LGX818) Combined With Cetuximab and With or Without the α-specific PI3K Inhibitor Alpelisib (BYL719) in Patients With Advanced BRAF-mutant Colorectal Cancer

J. Tabernero, et al.

Binimetinib

09/29/2014

ESMO

Overall Survival and Biomarker Results From a Phase 2 Study of MEK1/2 Inhibitor Binimetinib (MEK162) in Patients With Advanced NRAS-Mutant Melanoma

C. M. L. van Herpen, et al.

Selumetinib

09/28/2014

ESMO Congress 2014 - Madrid, Spain

A Phase I study of the MEK1/2 inhibitor selumetinib in combination with first-line chemotherapy regimens for NSCLC

E. Dean, et al.

Encorafenib

09/26/2014

ESMO Congress 2014 - Madrid, Spain

Ph Ib/II study of LEE011 (CDK4/6 inhibitor) and LGX818 (BRAF inhibitor) in BRAF‐mutant melanoma

M. H. Taylor, et. al

Encorafenib

09/26/2014

ESMO Annual Meeting - Madrid, Spain

Encorafenib (LGX818), an Oral BRAF Inhibitor, in Patients With BRAFV600E Metastatic Colorectal Cancer: Results of Dose Expansion in an Open-Label, Phase 1 Study

C. Gomez-Roca, et. al

Filanesib

06/13/2014

European Hematology Association

Phase 1 Study of Filanesib (ARRY-520) with Bortezomib (BTZ) and Dexamethasone (dex) in Relapsed or Refractory Multiple Myeloma (RRMM)

A. Chari, et al.